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Cultured Clostridium botulinum strains produce progenitor toxins designated as 12S,  16S,  and 19S 
toxins.  The 12S toxin consists of a neurotoxin (NTX,  7S) and a non-toxic non-hemagglutinin (NTNH).  
The 16S and 19S toxins are formed by conjugation of the 12S toxin with hemagglutinin (HA),  and the 
19S toxin is a dimer of the 16S toxin.  Type A cultures produce all 3 of these progenitor toxins,  while 
type E produces only the 12S toxin.  The 7S toxin is cleaved into heavy (H) and light (L) chains by a 
protease(s) in some strains,  and the H chain has 2 domains,  the N-terminus (Hn) and C-terminus (Hc).  
It has been reported that type A toxins bind to the intestinal cells or cultured cells via either HA or Hc.  
In this study,  we investigated the binding of type A and E toxins to Caco-2 cells using Western blot 
analysis.  Both the type E 7S and 12S toxins bound to the cells,  with the 7S toxin binding more strongly,  
whereas,  in the type A strain,  only the 16S/19S toxins showed obvious binding.  Pre-incubation of the 
type E 7S toxin with IgG against recombinant type E Hc signiﬁcantly inhibited the 7S toxin binding,  
indicating that Hc might be a main binding domain of the type E toxin.
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lostridium botulinum produces poisonous neuro-
toxins (NTX,  7S),  and the cultures can be 
classiﬁed into 7 types,  A to G,  based on the antige-
nicity of the 7S toxin.  The 7S toxin is produced as a 
single chain protein (single chain form,  approximately 
150kDa).  In the type A strain,  the cells produce a 
protease(s) which can cleave the 7S toxin to a light (L) 
chain (50kDa) and a heavy (H) chain (100kDa) linked 
by a disulﬁde bridge (di-chain form).  In the type E 
strain,  the cells produce no such protease,  and there-
fore,  the 7S toxin remains in a single chain form 
(Fig.  1A) [1].  Recently,  it has become clear that the 
L chain is a catalytic domain showing protease activ-
ity,  whereas,  the H chain has 2 domains: the 
N-terminus (Hn) is a channel-forming or transmem-
brane domain,  and the C-terminus (Hc) is a binding 
domain to the target neuronal cells [2,  3].
　 In culture liquid and foods,  the 7S toxin exists as 
various sizes of progenitor toxins that are composed 
of a 7S toxin and non-toxic components,  including a 
hemagglutinin (HA) and a non-toxic non-HA (NTNH).  
There are 3 kinds of progenitor toxins,  12S 
(300kDa),  16S (500kDa),  and 19S (900kDa) toxins 
(Fig.  1B).  The type A strain produces 12S,  16S,  
and 19S toxins,  the type B,  C,  and D strains pro-
duce 12S and 16S toxins,  while the type E and F 
strains produce only the 12S toxin.  The progenitor 
toxins dissociate into a 7S toxin and non-toxic compo-
nents under an alkaline condition.  The non-toxic 
components protect the 7S toxin against low pH and 
C
Acta Med.  Okayama,  2012
Vol.  66,  No.  3,  pp.  253ﾝ261
CopyrightⒸ 2012 by Okayama University Medical School.
Original Article http ://escholarship.lib.okayama-u.ac.jp/amo/
Received November 11, 2011 ; accepted December 9, 2011.
＊Corresponding author. Phone : ＋81ﾝ86ﾝ235ﾝ7157; Fax : ＋81ﾝ86ﾝ235ﾝ7162
E-mail : kuma@md.okayama-u.ac.jp (K. Oguma)
protease digestion across the gastrointestinal tract,  
and foster the process of botulism [4].
　 In food-borne botulism,  orally ingested toxins must 
traverse the gastrointestinal tract before arriving and 
aﬀecting the nerve endings.  Oguma et al.  found that 1) 
the 19S toxin is a dimer of the 16S toxin; 2) HA 
consists of 3 to 4 subcomponents designated HA-1,  -2,  
and -3 (3a and 3b); 3) HA3b and HA1 bind to sialic 
acid and galactose,  respectively,  existing on the sur-
face of intestinal cells,  cultured cells,  and erythro-
cytes; 4) type A,  B,  C,  and D HA-positive progeni-
tor toxins bind to the cells much more strongly than 
the 7S toxin via either HA1 or HA3b; 5) the binding 
occurs at both 4℃ and 37℃,  but internalization into 
the cells appears only at 37℃ [5-11].  Ohyama et al.  
reported that both the 7S and 16S toxins of types C 
and D were able to bind to IEC-6 cells (a rat intestinal 
epithelial cell line) and Caco-2 cells (a human colonic 
carcinoma cell line) at 4℃,  but the 16S toxin bound 
more strongly than the 7S toxin because the 16S toxin 
has HA; HA was important for higher binding of the 
16S toxin [12-14].  However,  Popoﬀ et al.  reported 
that both the type A 7S toxin and complex toxin (pro-
genitor toxin) bound to m-ICcl2 cells (a mouse intestinal 
epithelial cell line) and Caco-2 cells at a similar level 
via Hc [15,  16].
　 The type E strain produces only the 12S toxin,  
and its binding domain(s) to the intestinal cells has not 
yet been clariﬁed.  Caco-2 cells can diﬀerentiate into 
polarized cells,  and are connected by tight junction,  
as similar to human intestinal barriers [17].  Therefore,  
in this study,  we compared the binding properties of 
type A and E toxins to the Caco-2 cells,  in an attempt 
to determine the binding domain(s) of the type E toxin.
Materials and Methods
　 Production and puriﬁcation of botulinum 
toxins of type A and type E. Production and 
puriﬁcation of type A toxins from C. botulinum type A 
strain 62A were performed as described previously 
[18].  The spores were germinated at 35℃ overnight 
in 50ml of cooked meat medium (pH7.2; Becton,  
Dickinson and Company,  Sparks,  MD,  USA),  and 
then transferred to toxin production medium.  The 
medium was composed of 2ｵ peptone,  0.5ｵ yeast 
extract,  0.5ｵ glucose and 0.025ｵ sodium thioglyco-
late.  After incubation at 30℃ for 5 days,  the toxins 
were collected by acid (3 N H2SO4) precipitation.  The 
precipitates were suspended in distilled water,  centri-
fuged (8,700×g for 20min),  and re-suspended into 
0.2M phosphate buﬀer (pH6.0).  This preparation was 
then treated with protamine to remove RNAs.  
Thereafter,  the toxins were precipitated with a 60ｵ 
saturation of ammonium sulfate,  and dissolved in 
50mM acetate buﬀer (pH4.2).  The solution was then 
applied to an SP-Toyopearl 650S (Tosoh,  Tokyo,  
Japan) column.  The 16S/19S and 12S toxins were 
eluted with a linear gradient of NaCl (0-500mM).  
After dialysis against 10mM phosphate buﬀer 
(pH6.0),  the toxin fractions were applied to a lactose 
gel (EY Laboratories Inc.,  San Mateo,  CA,  USA) 
column.  The 12S toxin passed through the column,  
whereas the 16S/19S toxins bound to the column were 
eluted with the same buﬀer containing 0.2M lactose.  
To purify 7S toxin,  the 16S/19S toxins were dia-
254 Acta Med.  Okayama　Vol.  66,  No.  3Zhang et al.
A
single chain form
endogenous protease
di-chain form
L Hn Hc
L
Hn Hc
S S
S
S
B
19S toxin (900 kDa)
16S toxin (500 kDa)
12S toxin (300 kDa)
L Hn Hc
L Hn Hc
S S
S S
L Hn Hc
L Hn Hc
S S
S S
HA 7S
HA1 HA2 HA3 (3a, 3b) NTNH
HA1 HA2 HA3 (3a, 3b) NTNH
HA1 HA2 HA3 (3a, 3b) NTNH
NTNH
⬇
Fig. 1　 Schematic models of the structures of C. botulinum 7S 
toxin and progenitor toxins.  (A) The 7S toxin is synthesized as a 
single chain form protein,  and cleaved into the di-chain form by 
endogenous protease in some strains.  The di-chain form toxin is 
composed of a light (L) chain and a heavy (H) chain,  and the two 
chains are linked by a disulﬁde bond.  (B) The progenitor toxins 
consist of neurotoxin and nontoxic components.  The 12S toxin is 
formed by association of a neurotoxin with a nontoxic component 
having no HA activity (nontoxic non-HA, NTNH); the 16S toxin is 
formed by conjugation of the 12S toxin with HA; the 19S toxin is a 
dimer of the 16S toxin.  L,  L chain; Hc,  half C-terminal of H 
chain; Hn,  half N-terminal of H chain.
lyzed against 10mM phosphate buﬀer (pH8.0) to dis-
sociate them to 7S toxin and non-toxic components,  
and re-applied to the same lactose column.  The 7S 
toxin was collected in the path-through fraction.
　 Type E 7S and 12S toxins were puriﬁed from C. 
botulinum type E strain Iwanai according to the meth-
ods previously reported with slight modiﬁcations [19,  
20].  The spores were germinated under anaerobic 
conditions at 30℃ for 2 days in 50ml of cooked meat 
medium (pH7.2) supplemented with 1ｵ (w/v) prote-
ose peptone,  1ｵ (w/v) polypeptone,  1ｵ (w/v) lactal-
bumin hydrolysate,  1ｵ (w/v) yeast extract,  0.1ｵ 
(w/v) L-cysteine hydrochloride monohydrate and 1ｵ 
(w/v) glucose.  Then,  the culture was transferred to 
large-scale culture medium (pH6.3) consisting of 2ｵ 
(w/v) peptone,  0.5ｵ (w/v) yeast extract,  1ｵ (w/v) 
glucose and 0.025ｵ (w/v) sodium thioglycolate.  After 
incubation at 30℃ for 3 days,  the bacterial cells were 
collected by centrifugation at 10,000×g for 30min,  
and washed with 50mM acetate buﬀer (pH5.0).  The 
toxins were extracted with 200mM phosphate buﬀer 
(KH2PO4/Na2HPO4,  pH6.0) at 37℃ for 2h and then 
at 4℃ overnight.  The cell extract was precipitated 
with ammonium sulfate at 60ｵ saturation,  and col-
lected by centrifugation at 15,000×g for 15min.  The 
precipitate was dissolved in 20mM acetate buﬀer 
(pH6.0) and dialyzed against the same buﬀer.
　 Cell extract was loaded onto a CM-SepharoseTM 
Fast Flow (GE Healthcare Bio-Sciences AB,  Uppsala,  
Sweden) column previously equilibrated with 20mM 
acetate buﬀer (pH6.0).  The pass-through fractions 
were treated with Ribonuclease A from bovine pan-
creas (7.5µg/ml ﬁnal concentration) for 5h at 30℃,  
and then centrifuged at 1,000×g for 10min to remove 
RNAs.  The resultant supernatant was loaded onto a 
CM-Sepharose Fast Flow column equilibrated with 
20mM acetate buﬀer (pH6.0).  After washing with the 
same buﬀer,  the proteins were eluted with an expo-
nential gradient of NaCl (30-120mM) in equilibration 
buﬀer.  The toxic fractions were pooled,  concentrated 
and loaded onto a SephacrylTM S-200 High Resolution 
(GE Healthcare Bio-Sciences AB) gel ﬁltration column 
pre-equilibrated with 20mM acetate buﬀer (pH6.0).  
12S toxin was eluted in the ﬁrst peak.  Next,  the 
toxin was dialyzed against 10mM phosphate buﬀer 
(pH8.0) to dissociate 12S toxin to 7S toxin and NTNH,  
and loaded onto a Toyopearl DEAE-650S (Tosoh,  
Tokyo,  Japan) column equilibrated with the same buf-
fer.  7S toxin and NTNH were eluted with a linear 
gradient of NaCl (0-200mM).  All the centrifugation 
and dialysis steps were performed at 4℃.  All puriﬁ-
cation steps were carried out at room temperature.
　 Preparation of recombinant proteins. The 
recombinant type E NTNH (rE-NTNH) was produced 
by using a pET-32 Ek/LIC vector (Novagen,  Darmstadt,  
Germany).  The gene encoding whole NTNH was 
ampliﬁed from C. botulinum type E strain Iwanai by a 
polymerase chain reaction (PCR) using the following 
primers: for NTNH-F,  5ʼ-GACGACGACAAGATG
AAATAAATGGTAATTTAAATTG-3ʼ; and for 
NTNH-R,  5ʼ-GAGGAGAAGCCCGGTTTATATATT 
TTTTAATATCCATAGATA-3ʼ.  According to the 
manufacturerʼs protocol,  the PCR product was cloned 
into a pET-32 Ek/LIC vector.  After verifying the 
DNA sequence by an ABI PRISM 3100 Genetic 
Analyzer (Applied Biosystems),  the constructed plas-
mid was transformed into Escherichia coli BL21 (DE3) 
pLysS-competent cells.  The His-tagged proteins were 
expressed by addition of IPTG at 25℃,  puriﬁed by 
Ni-NTA Agarose (QIAGEN GmbH,  Hilden,  Germany) 
chromatography,  and then cleaved with recombinant 
Enterokinase (rEK),  which was subsequently elimi-
nated by an Enterokinase Cleavage Capture Kit 
(Novagen,  Darmstadt,  Germany).  Finally,  rE-NTNH 
proteins were obtained in pass-through fractions after 
applying the cleavage-protein solution to the Ni-NTA 
Agarose column.
　 Recombinant type E Hc (rE-Hc) was prepared in 
order to study the role of Hc and in particular its 
ability to interact with membranes.  The following 
primers were designed for ampliﬁcation of the gene 
fragment encoding Hc of C. botulinum type E strain 
Iwanai: for Hc-F,  5ʼ-CGCGGATCCGCGTCATATT
TTAATAAATTCTTTAAGAGAATTA-3ʼ; and for 
Hc-R,  5ʼ-CCGCTCGAGCGGTTATTTTTCTTGCC 
ATCCATGTTCTT-3.ʼ  The PCR product was digested 
by BamHI and XhoI and cloned into a pGEX-6P-3 vec-
tor (GE Healthcare Bio-Sciences AB) that was 
already restricted with the same enzymes.  After 
introducing pGEX-6P-3-rE-Hc into E. coli 21 (DE3) 
pLysS-competent cells,  the expression and puriﬁca-
tion of rE-Hc protein were performed according to the 
procedure described previously [21].
　 Preparation of antisera. Antisera against 
rE-NTNH,  rE-Hc and A-16S/19S toxins were gener-
ated by immunizing rabbits (New Zealand white 
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rabbits; 2.5kg,  female) as described previously [22].  
The rE-NTNH and rE-Hc were utilized with no pre-
treatment,  whereas,  the A-16S/19S toxins were made 
with 0.4ｵ Formalin treatment.  Initially,  200µg of 
each antigen was emulsiﬁed in an equal volume of 
Freundʼs complete adjuvant and injected subcutane-
ously.  Two weeks later,  the rabbit was given a second 
subcutaneous immunization of 200µg of antigen with 
Freundʼs incomplete adjuvant.  After 2 weeks,  a ﬁnal 
booster injection of 100µg of antigen was adminis-
tered intravenously without adjuvant.  One week later,  
the blood was collected from the rabbit,  and the 
antiserum was collected by centrifugation at 3,000g 
for 20min.  To partially purify IgG,  proteins in the 
serum were precipitated by 50ｵ saturated ammonium 
sulfate,  and dissolved in 17.5mM phosphate buﬀer 
(pH6.3).  After dialysis against the same buﬀer,  pro-
teins were added to a Toyopearl DEAE-650S column.  
The pass-through fractions which contained IgG were 
collected and stored at －80℃ until use.  All animal 
experiments were carried out in accordance with the 
animal experiment guidelines of Okayama University 
(OKU-2009318).  Eﬀorts were made to minimize the 
suﬀering of the animals.
　 Cell culture. Caco-2 cells (RIKEN Bio Resource 
Center) were grown in Dulbeccoʼs modiﬁed Eagleʼs 
medium (DMEM; GibcoTM Invitrogen Corporation,  
Grand Island,  NY,  USA) supplemented with 10ｵ 
fetal bovine serum (FBS),  penicillin (100IU/ml) and 
streptomycin (100µg/ml).  Cells were maintained in a 
humidiﬁed environment of 5ｵ CO2 at 37℃.
　 Toxin-binding assay. Caco-2 cells (2×105/
well) were seeded in 24-well plates (Greiner Bio-One,  
Frickenhausen,  Germany) and grown to 100ｵ conﬂu-
ence.  Toxins or proteins were suspended in 300µl of 
cold phosphate-buﬀered saline (PBS; pH6.5) to the 
indicated concentrations.  Cells were then incubated 
with toxins for 1h at 4℃,  washed three times with 
cold PBS,  and lysed with 150µl of SDS sample buf-
fer.  Proteins from 10µl of cell lysate were separated 
by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE),  and analyzed by Western blotting.  The 
intensity of detected bands was measured with Image 
Gauge Ver 4.0 (Fujiﬁlm,  Tokyo,  Japan).  The Western 
blotting with diﬀerent amounts of type A 16S/19S 
and type E 12S toxins was ﬁrst performed,  and the 
standard linear lines were prepared by assay the 
intensity of H chain and 7S toxin in type A and E,  
respectively.  Thereafter,  the levels of cell-bound type 
A and E toxins in the diﬀerent cell lysates (10µl) 
were estimated by using this standard lines after the 
Western blotting.  The quantity of toxins in 10µl of 
cell lysates thus obtained was multiplied by 15 to 
estimate the amounts of toxins in 150µl of whole cell 
lysates.
Results
　 Puriﬁcation of type A and E toxins. As 
shown in Fig.  2A,  we have successfully puriﬁed type 
A 7S,  12S,  and 16S/19S toxins.  As described in the 
Introduction,  the type A strain of C. botulinum pro-
duces endogenous protease(s) that can cleave the 7S 
toxin into a di-chain form.  Therefore,  the 7S toxin 
showed 2 bands of 50kDa and 100kDa corresponding 
to the L chain and H chain,  respectively,  on SDS-
PAGE in the presence of 2-mercaptoethanol (2-ME).  
The 16S/19S toxins demonstrated seven bands: the L 
chain and H chain of 7S toxin,  intact NTNH and four 
subcomponents of HA (HA1,  HA2,  HA3a,  and HA3b).  
The SDS-PAGE pattern of the type A 12S toxin 
showed the disappearance of a 120-kDa intact NTNH 
accompanied by the appearance of a 106-kDa band,  
indicating that the NTNH of 12S toxin was cleaved at 
the N-side of Phe-145 by protease,  as reported previ-
ously [23].  The type A 12S toxin is comprised of the 
7S toxin and cleaved NTNH.  Unlike the type A 
strain,  the type E strain does not produce protease,  
and the 7S toxin exists as a single chain toxin.  
Therefore,  the type E 7S toxin demonstrated a 150-
kDa band on SDS-PAGE in the presence of 2-ME 
(Fig.  2B).  The type E 12S toxin was comprised of a 
7S toxin (～150kDa) and an NTNH (～130kDa).
　 Binding of type A toxins to Caco-2 cells.
As described above,  the functions of nontoxic compo-
nents during passage of type A progenitor toxins 
through the intestinal barrier remain controversial.  
To further investigate the binding properties of type 
A toxins,  a toxin-binding assay was conducted by using 
the Western blotting method,  as described under the 
Materials and Methods.  The 7S and 12S toxins 
showed no binding to Caco-2 cells,  whereas the 
16S/19S toxins exhibited signiﬁcantly high binding 
(Fig.  3A).  These results indicate that the binding of 
type A toxins to Caco-2 cells is mediated by HA.  This 
lends support to our previous report that HA plays 
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crucial roles in the binding of type A toxins to intesti-
nal microvilli and erythrocytes [8].  The intensity of 
the H chain band of 7S toxin was measured,  and the 
amounts of bound toxins were calculated by the stan-
dard linear line (Fig.  3B).  The binding amounts of 
16S/19S toxins at the ﬁnal concentrations of 50,  100,  
and 200nM were 1.74,  2.55,  and 4.38 pmol,  respec-
tively.
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Fig. 2　 SDS-PAGE patterns of the puriﬁed toxins and nontoxic components.  Proteins were separated by SDS-PAGE using 12% poly-
acrylamide gel in the presence of 2-ME,  and stained by Coomassie brilliant blue R-250.  (A) Type A 7S,  12S,  and 16S/19S toxins.  (B) 
Type E 7S,  12S,  and NTNH.  M,  standard molecular mass markers.
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Fig. 3　 Binding of type A toxins to Caco-2 cells.  (A) Caco-2 cells were incubated with type A 7S,  12S,  and 16S/19S toxins at the ﬁnal 
concentration of 50,  100,  and 200nM for 1h at 4℃.  Toxins bound to cells were detected by Western blotting using anti-A-16S/19S IgG.  
(B) The standard linear line was ﬁrst prepared by assay the intensity of H chain after doing the Western blotting with diﬀerent amounts of 
16S/19S toxins.  Then,  the levels of cell-bound toxins in preparations of ①,  ②,  and ③ of (A) were estimated by using this standard line.  
(－),  only cell lysate; 16S/19S (＋),  only 16S/19S toxins.
　 Binding of type E toxins to Caco-2 cells.
We next investigated the binding properties of the type 
E 7S and 12S toxins.  The eﬀects of temperature and 
time on the binding and the absorption of type E toxins 
were ﬁrst examined.  The type E 7S (Fig.  4A) and 
12S (Fig.  4B) toxins were found to bind to Caco-2 
cells in a time-dependent manner at 4℃ and 37℃.  
The level of binding activity was signiﬁcantly higher 
at 37℃ than that at 4℃,  suggesting that some toxins 
may be internalized into the cells at 37℃ after bind-
ing.
　 The toxin-binding activities at various concentra-
tions of type E 7S and 12S toxins were also examined.  
The amount of binding of the type E 7S and 12S tox-
ins increased as the concentrations of the toxins 
increased (Fig.  5A).  By quantifying the intensity of 
the 7S toxin band,  the level of 7S binding activity at 
the ﬁnal concentrations of 50,  100,  and 200nM was 
estimated to be 0.27,  0.41,  and 1.01 pmol,  respec-
tively.  On the other hand,  the level of binding activity 
for the 50 and 100nM 12S toxin dilutions was unfor-
tunately too low for calculation,  and the level of 
binding activity of the 12S toxin at the ﬁnal concen-
tration of 200nM was calculated to be 0.2 pmol (Fig.  
5B).  Thus,  the level of binding activity of the 7S 
toxin was approximately 5-fold greater than that of the 
12S toxin.  We also found that neither NTNH nor 
rNTNH exhibited any detectable binding to Caco-2 
cells (data not shown).  Therefore,  the 7S toxin,  but 
not the NTNH,  might play a key role in the binding of 
type E toxins to Caco-2 cells.
　 Inhibitory eﬀect of antibody on the binding of 
type E toxins. The above results indicate that the 
mechanism of binding of type E toxins to Caco-2 cells 
is diﬀerent from the mechanism of binding of type A 
toxins to Caco-2 cells,  and the binding domain(s) of the 
type E toxins may exist in the 7S toxin.  The 7S toxin 
has been reported to bind to neuronal cells via Hc 
[24,  25].  To assess whether the Hc domain is 
involved in the interaction with the receptor on Caco-2 
cells,  an inhibition assay was performed using anti-
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Fig. 5　 Eﬀect of the concentrations of type E toxins on their binding to Caco-2 cells.  (A) Caco-2 cells were incubated with the type E 
7S and 12S toxins (ﬁnal concentrations of 50,  100,  and 200nM) for 1h at 4℃.  Toxins in 10µl of the cell lysates were detected by 
Western blotting using anti-rE-Hc IgG.  (B) The standard linear line was ﬁrst prepared by assay the intensity of 7S toxin after doing the 
Western blotting with diﬀerent amounts of 12S toxins.  Then,  the levels of cell-bound toxins in the preparations of ①,  ②,  ③,  ④,  ⑤,  and 
⑥ of (A) were estimated by using this standard line.  (－),  only cell lysate; 12S (＋),  only 12S toxin.
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Fig. 4　 Temperature dependence and time course of the binding 
of type E toxins to Caco-2 cells.  Cells were incubated with 7S 
toxin (A) or 12S toxin (B) at 100nM for 5,  20,  and 60min at 4℃ 
or 37℃,  respectively.  Toxins bound to the cells were detected 
using anti-rE-Hc IgG.
rE-Hc IgG.  Toxins were incubated with speciﬁed 
concentrations of IgG for 1h at 37℃ prior to the 
toxin-binding assay.  Pre-incubation of the 7S toxin 
with anti-rE-Hc IgG resulted in an obvious decrease 
of 7S toxin binding.  The addition of 0.2mg/ml of 
anti-rE-Hc IgG led to an approximately 50ｵ reduc-
tion in the toxin binding (Fig.  6A).  On the other hand,  
pre-incubation of the 12S toxin with anti-rE-Hc IgG 
did not inhibit the toxin binding to Caco-2 cells (Fig.  
6B).  These data indicate that the type E 7S toxin 
may bind to Caco-2 cells mainly via Hc.
Discussion
　 Binding of type A and E toxins to Caco-2 cells was 
observed.  Recent research has shown that botulinum 
toxins bind to the cell surface at 4℃,  but are not 
internalized [13].  Therefore,  in this study,  the toxin-
binding experiments were done at 4℃.  The binding of 
type A 7S,  12S,  and 16S/19S toxins to Caco-2 cells 
was ﬁrst investigated.  As we expected,  only HA- 
positive 16S/19S toxins bound to Caco-2 cells,  which 
corresponds to our previous research.  Thus,  HA is 
considered to be essential for the binding of type A 
16S/19S toxins.  However,  Popoﬀ et al.  documented 
that Hc is important for the binding and absorption of 
type A 7S and progenitor toxins [15,  16].  What led 
to these diﬀerent conclusions is not clear.  The conﬂict 
might be related to the use of diﬀerent detection sys-
tems or diﬀerent ﬁnal concentrations of toxins 
between the 2 experiments.
　 We also investigated the binding of type E 7S and 
12S toxins (containing no HA) to Caco-2 cells.  In 
contrast to type A toxins,  the 7S toxin exhibited a 
higher level of binding than the 12S toxin,  and no 
binding of native NTNH or rNTNH to Caco-2 cells 
was observed.  Hence,  it was considered that the bind-
ing domain may exist in the 7S toxin.  In order to 
conﬁrm this,  inhibition assays of antibody were con-
ducted.  Pre-incubation of the 7S toxin with anti-rE-
Hc IgG led to signiﬁcant,  but not complete inhibition,  
even though a large amount of IgG was employed.  
This indicates that Hc is the main binding domain,  but 
other domain(s) such as the Hn or L chain might also 
act in binding.  In contrast,  no obvious inhibition by 
anti-rE-Hc IgG on 12S toxin binding was observed.  
As to the reason for the low binding activity of the 
12S toxin,  we suppose that,  in the 12S toxin,  the Hc 
domain might be covered by NTNH or the structure of 
the Hc domain might be changed after 7S toxin associ-
ates with NTNH.  This might also explain why anti-
rE-Hc IgG did not inhibit the 12S toxin binding.
　 In this work,  type A 16S/19S toxins showed 
slightly higher binding than type E toxins.  We specu-
late that there are more type A HA receptors than 
type E toxin-binding receptors on the cell surface.  
The HA of type A,  B,  C,  and D progenitor toxins has 
been reported to bind to galactose and/or sialic acid 
on the cells [5-14],  while the intestinal receptors of 
type E toxins remain unclear.  Regarding the recep-
tors,  synaptic vesicle glycoprotein 2 (SV2) proteins 
have been reported to act as receptors for type A and 
type E 7S toxins on neuronal cells [26,  27].  Popoﬀ 
et al.  reported that the type A 7S toxin binds to the 
SV2C on the intestinal cells via Hc [15].  Therefore,  
in a future study we will investigate whether SV2 
proteins of intestinal cells act as receptors for type E 
7S toxin.
　 In order to induce food-borne botulism,  the toxins 
must be absorbed from the small intestine.  Our previ-
ous work showed that the type C 16S toxin was 
internalized into HT-29 cells (a human colon carcinoma 
grade II cell line) within at least 4min after adminis-
tration at 37℃ [9].  In the present study,  we investi-
gated the binding of type E toxins to Caco-2 cells at 
4℃ and 37℃.  Both 7S and 12S toxins showed higher 
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7S 7S
Fig. 6　 Eﬀect of antibody on the binding of type E 7S (A) and 12S (B) toxins.  Prior to incubation with Caco-2 cells,  the 7S and 12S 
toxins (100nM ﬁnal concentration) were incubated with anti-rE-Hc IgG (ﬁnal concentrations of 0,  0.01,  0.1,  and 0.2mg/ml) for 1h at 37℃.  
Toxins bound to the cells were detected by Western blotting using anti-rE-Hc IgG.
binding activity at 37℃ than 4℃.  We consider that 
some amounts of toxins may have been internalized 
into the cells after binding at 37℃.  Since (1) no 
studies have been conducted into the internalization of 
type E toxins through intestinal cells,  and (2) Caco-2 
monolayers incubated on membrane ﬁlters are gener-
ally used to investigate the permeability of drugs and 
chemicals [17],  we are currently planning to investi-
gate the transcytosis of type E toxins by using a 
Caco-2 cell monolayer system.
　 Previously,  it was reported that the progenitor 
toxins dissociate into a 7S toxin and non-toxic compo-
nents after absorption from the small intestine,  in the 
lacteal vessels [28].  If type A and E 7S toxins are 
absorbed from the small intestine,  the progenitor 
toxins must dissociate into 7S toxin and nontoxic 
components before reaching the small intestine.  We 
are also planning to clarify this point by subjecting the 
progenitor toxins to diﬀerent pH levels and to diﬀer-
ent amounts of the gastrointestinal juice,  in order to 
mimic conditions in the gastrointestinal tract.
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